Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial
-
Published:2024-09
Issue:
Volume:
Page:
-
ISSN:0002-8703
-
Container-title:American Heart Journal
-
language:en
-
Short-container-title:American Heart Journal
Author:
De Cock EmmanuelORCID, Kautbally Shakeel, Timmermans Frank, Bogaerts Kris, Hanet Claude, Desmet Walter, Gurné Olivier, Vranckx Pascal, Hiltrop Nick, Dujardin Karl, Vanduynhoven Philippe, Vermeersch Paul, Pirlet Charles, Hermans Kurt, Van Reet Bert, Ferdinande Bert, Aminian Adel, Dewilde Willem, Guédès Antoine, Simon François, De Roeck Frederic, De Vroey Frédéric, Jukema J. Wouter, Sinnaeve Peter, Buysschaert IanORCID
Reference27 articles.
1. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study;Roth;J Am Coll Cardiol,2020 2. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial 3. The changing landscape of atherosclerosis;Libby;Nature,2021 4. Inflammation in acute myocardial infarction: the good, the bad and the ugly;Matter;Eur Heart J,2024 5. hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study;Carrero;J Am Heart Assoc,2019
|
|